Targets › IL2
16 programs from 16 companies in 31 trials: 16 Phase 1, 11 Phase 2, 3 Phase 3, 1 Phase 4; Oncology, Immunology, Other; next expected readout Nov 2026.
Cytokine produced by activated CD4-positive helper T-cells and to a lesser extend activated CD8-positive T-cells and natural killer (NK) cells that plays pivotal roles in the immune response and tolerance. Binds to a receptor complex composed of either the high-affinity trimeric IL-2R (IL2RA/CD25, IL2RB/CD122 and IL2RG/CD132) or the low-affinity dimeric IL-2R (IL2RB and IL2RG). (UniProt, P60568)
Open in Phaseline: the race on IL2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shanghai Pulmonary Hospital, Shanghai, China | Vγ2Vδ2 T lymphocyte-based immunotherapy (zoledronic acid/interleukin 2) Drug combination that amplifies Vγ2Vδ2 T cells via zoledronic acid (FDPS inhibitor) and IL | IL2, FDPS | Phase 4 | MDR-TB | Aug 2027 |
| Innovent Biologics (Suzhou) | IBI363 Mutated IL-2 cytokine fused to anti-PD-1 antibody; combines IL-2 pathway stimulation with | PDCD1, IL2 | Phase 3 | Colorectal Cancer; Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer; Melanoma; Solid Tumors or Lymphoma … | Nov 2026 |
| Nektar Therapeutics | Rezpegaldesleukin (NKTR-358) Pegylated recombinant human interleukin-2 | IL2RA, IL2 | Phase 3 | Moderate-to-Severe Atopic Dermatitis; Moderate to Severe Atopic Dermatitis; Type 1 Diabetes Mellitus | Dec 2026 |
| Coya Therapeutics | COYA 302 Low-dose IL-2 to enhance regulatory T cell function combined with abatacept (CTLA-4 Ig) to | IL2, CD80, CD86 | Phase 2 | Amyotrophic Lateral Sclerosis (ALS) | Apr 2027 |
| Regeneron Pharmaceuticals | REGN10597 PD-1-IL2Ra-IL2 immunotherapy | PDCD1, IL2RA, IL2 | Phase 2 | Ovarian Cancer; Non Small Cell Lung Cancer; Melanoma | Jun 2028 |
| Salspera | Salmonella-IL2 (Saltikva) Attenuated Salmonella Typhimurium expressing IL-2 | IL2 | Phase 2 | Metastatic Pancreatic Cancer | Dec 2030 |
| Second Xiangya Hospital of Central South University | Human interleukin-2 (IL-2) Interleukin-2 cytokine | IL2 | Phase 2 | Chronic Spontaneous Uriticaria | – |
| Aulos Bioscience | AU-007 (imneskibart) Monoclonal antibody that binds to IL-2 and inhibits IL-2Rα binding | IL2 | Phase 1 | Advanced Solid Tumor | Feb 2027 |
| Trutino Biosciences | ODC-IL2 Conditionally activated IL-2 prodrug | IL2 | Phase 1 | Advanced Solid Tumors | Mar 2027 |
| Asher Biotherapeutics | etakafusp alfa (AB248) CD8+ T cell selective interleukin-2 agonist | IL2 | Phase 1 | Solid Tumor | May 2027 |
| HCW Biologics | HCW9302 IL-2 fusion protein | IL2 | Phase 1 | Alopecia Areata(AA) | Jul 2027 |
| Ascendis Pharma Oncology Division | TransCon IL-2 β/γ IL-2 receptor agonist with extended half-life via TransCon technology | IL2 | Phase 1 | Advanced Solid Tumor | Aug 2027 |
| Medicenna Therapeutics | MDNA11 Beta-only IL-2 receptor agonist fused to albumin | IL2 | Phase 1 | Advanced Solid Tumor | Oct 2028 |
| Synthekine | STK-012 Engineered Interleukin-2 (IL-2) selective for antigen-activated T cells | IL2 | Phase 1 | Advanced Solid Tumor | Jan 2029 |
| AstraZeneca | AZD6750 CD8-targeted IL-2 immunomodulator | IL2 | Phase 1 | Melanoma | Oct 2029 |
| Iovance Biotherapeutics | IOV-3001 Modified interleukin-2 fusion protein | IL2 | Phase 1 | Unresectable Melanoma | Jun 2032 |
Advanced Solid Tumor (6) Melanoma (5) Moderate-to-Severe Atopic Dermatitis (2) Colorectal Cancer (1) Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer (1) Solid Tumors or Lymphoma (1) Solid Malignancies or Lymphomas (1) Advanced Malignancies (1) IBI363 + Chemotherapy (1) Amyotrophic Lateral Sclerosis (ALS) (1) Moderate to Severe Atopic Dermatitis (1) Type 1 Diabetes Mellitus (1)
mixed (8), protein or peptide (5), small molecule (3)
Innovent Biologics (Suzhou) (1) AstraZeneca (1) Medicenna Therapeutics (1) Coya Therapeutics (1) Synthekine (1) Nektar Therapeutics (1) HCW Biologics (1) Shanghai Pulmonary Hospital, Shanghai, China (1) Asher Biotherapeutics (1) Regeneron Pharmaceuticals (1) Salspera (1) Iovance Biotherapeutics (1) Aulos Bioscience (1) Second Xiangya Hospital of Central South University (1) Ascendis Pharma Oncology Division (1) Trutino Biosciences (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.